PARP1/CDK12-IN-2
PARP1/CDK12-IN-2 is a selective dual PARP1/CDK12 inhibitor with an IC50 of 42 nM for CDK12 and an IC50 of 35 nM for PARP1. PARP1/CDK12-IN-2 inhibits CDK13. PARP1/CDK12-IN-2 induces Apoptosis and induces G2/M phase arrest. PARP1/CDK12-IN-2 exhibits anticancer activity against breast cancer and lung cancer. PARP1/CDK12-IN-2 can be used for research on triple-negative breast cancer.
For research use only. We do not sell to patients.
- Formula: C35H37ClN8O4S
- Molecular Weight:701.24
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
PARP1 35 nM (IC50) |
CDK12 42 nM (IC50) |
CDK13 |
PARP2 >10000 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
0.19 μM
|
Antiproliferative activity against human Hela cells assessed as viability reduction incubated 7 days by MTT assay.
Antiproliferative activity against human Hela cells assessed as viability reduction incubated 7 days by MTT assay.
|
42632193 |
| MIA PaCa-2 | IC50 |
0.15 μM
|
Antiproliferative activity against human Miapaca-2 cells assessed as viability reduction incubated 7 days by MTT assay.
Antiproliferative activity against human Miapaca-2 cells assessed as viability reduction incubated 7 days by MTT assay.
|
42632193 |
| KYSE-150 cell line | IC50 |
0.23 μM
|
Antiproliferative activity against human Kyse-150 cells assessed as viability reduction incubated 7 days by MTT assay.
Antiproliferative activity against human Kyse-150 cells assessed as viability reduction incubated 7 days by MTT assay.
|
42632193 |
| ASPC1 | IC50 |
0.91 μM
|
Antiproliferative activity against human Aspc-1 cells assessed as viability reduction incubated 7 days by MTT assay.
Antiproliferative activity against human Aspc-1 cells assessed as viability reduction incubated 7 days by MTT assay.
|
42632193 |
| A549 | IC50 |
0.41 μM
|
Antiproliferative activity against human A549 cells assessed as viability reduction incubated 7 days by MTT assay.
Antiproliferative activity against human A549 cells assessed as viability reduction incubated 7 days by MTT assay.
|
42632193 |
| MDA-MB-231 | IC50 |
0.23 μM
|
Antiproliferative activity against human MDA-MB-231 cells assessed as viability reduction incubated 7 days by MTT assay.
Antiproliferative activity against human MDA-MB-231 cells assessed as viability reduction incubated 7 days by MTT assay.
|
42632193 |
| SK-BR-3 | IC50 |
0.06 μM
|
Antiproliferative activity against human SK-BR-3 cells assessed as viability reduction incubated 7 days by MTT assay.
Antiproliferative activity against human SK-BR-3 cells assessed as viability reduction incubated 7 days by MTT assay.
|
42632193 |
| MCF7 | IC50 |
0.30 μM
|
Antiproliferative activity against human MCF-7 cells assessed as viability reduction incubated 7 days by MTT assay.
Antiproliferative activity against human MCF-7 cells assessed as viability reduction incubated 7 days by MTT assay.
|
42632193 |
| Hs-578T | IC50 |
0.15 μM
|
Antiproliferative activity against human HS578T cells assessed as viability reduction incubated 7 days by MTT assay.
Antiproliferative activity against human HS578T cells assessed as viability reduction incubated 7 days by MTT assay.
|
42632193 |
In Vitro
PARP1/CDK12-IN-2 (Compound 20b) is a dual CDK12/PARP1 inhibitor with an IC50 value of 42 nM for CDK12 and an IC50 value of 35 nM for PARP1, and is inactive against PARP2 (>10000 nM)[1].
PARP1/CDK12-IN-2 (200 nM) potently inhibits CDK12/13 and exhibits moderate to weak activity against CDK1, CDK4, CDK6, CDK8, CDK18, and CDK19[1].
PARP1/CDK12-IN-2 exhibits moderate in vitro metabolic stability in mouse liver microsomes, T1/2 = 123 min, CLint = 0.0282 mL/min/mg[1].
PARP1/CDK12-IN-2 (7 days) inhibits the proliferation of nine cancer cell lines, with IC50 values ranging from 0.06 to 0.91 µM, and an IC50 value of 0.23 µM against MDA-MB-231[1].
PARP1/CDK12-IN-2 (0-300 nM) concentration-dependently inhibited colony formation of MDA-MB-231, MCF-7, and A549 cells, and completely inhibited the growth of MDA-MB-231 and MCF-7 at 300 nM[1].
PARP1/CDK12-IN-2 (0.3-3 µM) induces apoptosis and G2/M phase arrest in MDA-MB-231 cells, with Western blot changes observed at 0.3-3 µM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | CL_obs | T1/2 | AUClast | AUCinf | MRTINF_obs | Vd |
|---|---|---|---|---|---|---|---|---|
| Rat[1] | 5 mg/kg | i.v. | 16.2 mL/min/kg | 1.41 h | 5325 ng·h/mL | 5336 ng·h/mL | 0.281 h | 1.92 L/kg |
Chemical Information
-
Molecular Weight 701.24
-
Formula C35H37ClN8O4S
-
SMILES
NC(C1=CC=CC2=C1N=C(C3=CC=C(N([C@@H]4CC[C@@H](NC5=NC=C(Cl)C(NC6=CC=CC=C6S(C(C)C)(=O)=O)=N5)CC4)C(C)=O)C=C3)N2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)